Literature DB >> 18502335

Follow up approaches in thyroid cancer: a risk adapted paradigm.

R Michael Tuttle1, Rebecca Leboeuf.   

Abstract

The primary goal in the follow up of thyroid cancer patients is to identify and treat persistent and recurrent disease at a time that minimizes morbidity and disease specific mortality. This article presents a risk-adapted follow-up paradigm to guide both intensity and methodology of follow-up testing based on initial risk stratification, ongoing risk stratification, and secondary risk stratification that incorporates each of the well-known risk factors for recurrence and death from thyroid cancer, with a response to therapy variable as well as duration of disease-free survival. With a proper understanding of the biology of the disease and with accurate assessments of response to therapy, clinicians are better able to tailor a risk-appropriate follow-up approach to individual patients, minimizing excessive testing while still providing adequate testing to detect clinically significant disease recurrence in a timely fashion.

Entities:  

Mesh:

Year:  2008        PMID: 18502335     DOI: 10.1016/j.ecl.2008.02.008

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  25 in total

1.  Differentiated thyroid cancer incidentally detected by ¹⁸F-FDG PET/CT: patient's future in a hot-spot?

Authors:  Silvia Morbelli; Marcello Bagnasco
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08       Impact factor: 9.236

Review 2.  Post-treatment surveillance of thyroid cancer.

Authors:  L Y Wang; I Ganly
Journal:  Eur J Surg Oncol       Date:  2017-07-19       Impact factor: 4.424

3.  Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission?

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Leonard Wartofsky
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

Review 4.  Nodal metastases in thyroid cancer: prognostic implications and management.

Authors:  Laura Y Wang; Ian Ganly
Journal:  Future Oncol       Date:  2016-03-07       Impact factor: 3.404

Review 5.  European Laryngological Society: ELS recommendations for the follow-up of patients treated for laryngeal cancer.

Authors:  Ricard Simo; Patrick Bradley; Dominique Chevalier; Frederik Dikkers; Hans Eckel; Nayla Matar; Giorgio Peretti; Cesare Piazza; Mark Remacle; Miquel Quer
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-09       Impact factor: 2.503

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?

Authors:  Arnoldo Piccardo; Matteo Puntoni; Giulia Ferrarazzo; Luca Foppiani; Gianluca Bottoni; Vania Altrinetti; Giorgio Treglia; Mehrdad Naseri; Bassam Dib; Manlio Cabria; Pierpaolo Trimboli; Michela Massollo; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236

Review 8.  Treatment and follow-up of low-risk patients with thyroid cancer.

Authors:  Martin Schlumberger; Isabelle Borget; Camila Nascimento; Maryse Brassard; Sophie Leboulleux
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

Review 9.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

10.  The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.

Authors:  E M Triviño Ibáñez; M A Muros; E Torres Vela; J M Llamas Elvira
Journal:  Endocrine       Date:  2015-07-30       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.